

A study to assess the efficacy and safety of bb2121 in people who have Myeloma that is not responsive after treatment or who had Myeloma which has returned after a period of treatment

Estado
EC Finalizado

Tipo de Participantes
No aportado

Rangos de Edad
Mayores de 64 , Adultos (18-64 años)

Género
Ambos

Fases
Fase II

Participantes esperados
228

Resultados
Sin resultados

Bajo nivel intervención
No

Enfermedad rara
Si

Cobertura geográfica
Sin determinar

Ámbitos del ensayo
tratamiento, seguridad, eficacia,
farmacocinética, farmacodinámica,
farmacogenómica

Terapia avanzada
Terapia génica

Información

Identificador
2023-505183-10-00 (CTIS)

Cod. Protocolo
bb2121-MM-002

Transicionado 2018-000264-28

Área terapéutica
Enfermedades [C] - Cáncer [C04]

Enfermedad investigada
Relapsed and refractory multiple myeloma (RRMM), multiple myeloma (MM) with progression within 18 months of initial treatment/ or newly diagnosed multiple myeloma (NDMM) with suboptimal response post autologous stem cell transplant (ASCT) (Cohort 3 only)

Título Científico

A PHASE 2, MULTI-COHORT, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BB2121 IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA AND IN SUBJECTS WITH CLINICAL HIGH-RISK MULTIPLE MYELOMA

Justificación

No aportado

Objetivo Principal

The primary objective of the study is to evaluate the efficacy of bb2121, of bb2121 in combination with lenalidomide maintenance, and of bb2121 with talquetamab as bridging therapy

Variables de Evaluación Primaria

Overall response rate (ORR) (Cohort 1)

Complete response (CR) rate Cohort 1b, Cohort 2a, Cohort 2b, Cohort 2c, and Cohort 3

Momentos temporales de evaluación primaria

No aportado

Objetivo Secundario

Evaluate additional efficacy parameters of bb2121

Characterize the expansion and persistence of chimeric antigen receptor (CAR) + T cells, in the peripheral blood (cellular kinetics-pharmacokinetics [PK])

Evaluate the development of an anti-CAR antibody response

Evaluate changes in health-related quality of life (HRQoL)

Cohort 3 only: Evaluate additional efficacy parameters of bb2121 in combination with lenalidomide maintenance

Cohort 3 only: Evaluate feasibility of initiating lenalidomide maintenance therapy post-bb2121 infusion

Variables de Evaluación Secundaria

Complete response (CR) rate (Cohort 1)

Overall response rate (ORR) Cohort 1b, 2a, b, and Cohort 3

Very good partial response (VGPR) rate (Cohort 2c)

Time to response (TTR)

Duration of response (DoR)

Progression-free survival (PFS)

Time to progression (TTP)
 Overall survival (OS)
 Pharmacokinetics
 Immunogenicity
 Health-related Quality of Life (HRQoL)
 Feasibility of lenalidomide maintenance therapy post-bb2121 infusion (Cohort 3)

Momentos temporales de evaluación secundaria

No aportado

Criterios de Inclusión

Subject is 18 years of age at the time of signing the informed consent form (ICF) Male subjects must: Practice true abstinence or agree to use a condom during sexual contact with a pregnant female or a FCBP, even if he has undergone a successful vasectomy from screening until at least 1 year following LD chemotherapy Refrain from tissue donation including sperm or any other tissue/blood/organ donations from screening until at least 1 year following LD chemotherapy. Cohorts 1 and 2 only, subject has measurable disease, defined as: M-protein (serum protein electrophoresis [sPEP] or urine protein electrophoresis [uPEP]): sPEP 0.5 g/dL or uPEP 200 mg/24 hours and/or Light chain MM without measurable disease in the serum or urine: Serum immunoglobulin free light chain 10 mg/dL and abnormal serum immunoglobulin kappa lambda free light chain ratio Subjects with one of the following cohort specific requirements: Cohort 1 RRMM subjects with 3 prior anti-myeloma treatment regimens: Subject must have received at least 3 prior anti-myeloma treatment regimens. Note: induction with or without hematopoietic stem cell transplant and with or without maintenance therapy is considered a single regimen Subject must have undergone at least 2 consecutive cycles of treatment for each regimen, unless PD was the best response to the regimen Subject must have received prior treatment with a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 antibody Subject has evidence of PD on or within 60 days of the most recent prior treatment regimen Subject achieved a response (minimal response [MR] or better) to at least 1 prior treatment regimen Cohort 2 subjects with 1 prior anti-myeloma treatment regimen: Subject must have received only 1 prior anti-myeloma treatment regimen. Note: induction with or without hematopoietic stem cell transplant and with or without maintenance therapy is considered a single regimen Subject must have the following HR factors: Early relapse defined as: Cohort 2a: PD < 18 months since date of start of initial therapy. Initial therapy must contain induction, ASCT (single or tandem) and lenalidomide containing maintenance Cohort 2b: PD < 18 months since date of start of initial therapy which must contain at minimum, a proteasome inhibitor, an immunomodulatory agent and dexamethasone Cohort 2c: Subject must have received minimum 3 cycles of induction therapy which must contain at minimum, a proteasome inhibitor, an immunomodulatory agent and dexamethasone. Subjects must have had ASCT (single or tandem) AND < VGPR (excluding PD) at first assessment between 70 to 110 days after last ASCT, with initial therapy without consolidation and maintenance Subject must have Eastern Cooperative Oncology Group (ECOG) performance status 1 Subject must have recovery to Grade 1 or baseline of any nonhematologic toxicities due to prior treatments, excluding alopecia and Grade 2 neuropathy Subject must have adequate vascular access for leukapheresis Subject must understand and voluntarily sign an ICF prior to any study-related assessments/procedures being conducted Subject is willing and able to adhere to the study visit schedule and other protocol requirements as well as agrees to continued follow up for up to 15 years as mandated by the regulatory guidelines for gene therapy trials Female subjects of childbearing potential (FCBP3) must: Have a negative pregnancy test(s) as verified by the Investigator, prior to the first dose of study treatment. This applies even if the subject practices true abstinence from heterosexual contact: -All subjects who receive LD chemotherapy/bb2121: Have negative pregnancy tests as verified by the Investigator, prior to LD chemotherapy. Either commit to true abstinence from heterosexual contact or agree to use, and be able to comply with highly effective measures of contraception without interruption, from screening through at least 1 year following LD chemotherapy. Contraception for FCBP must include highly effective methods of contraception from screening until -All subjects receiving LD chemotherapy/bb2121: until at least 1 year following LD chemotherapy. Agree to abstain from breastfeeding during study participation for at least 1 year following LD

chemotherapy. Refrain from tissue donation including egg cell donation or any other tissue/blood/organ donations until at least 1 year following LD chemotherapy.

Criterios de Exclusión

Subject used any investigational agents within 14 days prior to leukapheresis. Subject with prior history of malignancies, other than MM, unless the subject has been free of the disease for 5 years with the exception of the following noninvasive malignancies: a. Basal cell carcinoma of the skin b. Squamous cell carcinoma of the skin c. Carcinoma in situ of the cervix d. Carcinoma in situ of the breast e. Incidental histologic finding of prostate cancer (T1a or T1b using the TNM [tumor, nodes, metastasis] clinical staging system) or prostate cancer that is curative. Subject is a female who is pregnant, nursing, or breastfeeding, or who intends to become pregnant during participation in the study. Subject received any of the following within the last 14 days prior to leukapheresis: a. Plasmapheresis b. Major surgery (as defined by the investigator) c. Radiation therapy other than local therapy for myeloma associated bone lesions d. Use of any systemic anti-myeloma drug therapy. Subject with known hypersensitivity to any component of bb2121 product, cyclophosphamide, fludarabine, and/or tocilizumab. Subject has any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study. Subject has any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study. This includes systemic fungal, bacterial, viral, or other infection that is uncontrolled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antimicrobial treatment) or requiring IV antimicrobials for management. Subject has any condition that confounds the ability to interpret data from the study. Subject with known central nervous system (CNS) involvement with myeloma. Subject has clinical evidence of pulmonary leukostasis and disseminated intravascular coagulation. History or presence of clinically relevant CNS pathology such as epilepsy, seizure, paresis, aphasia, stroke, subarachnoid hemorrhage or other CNS bleed, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, or psychosis. Subject with a history of Class III or IV congestive heart failure (CHF) or severe nonischemic cardiomyopathy, unstable or poorly controlled angina, myocardial infarction, or ventricular arrhythmia within the previous 6 months prior to starting study treatment. Subject with active or history of plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes), or clinically significant amyloidosis. Subject has nonsecretory MM. Subject has any of the following laboratory abnormalities: a. Absolute neutrophil count (ANC) < 1,000/L b. Platelet count < 50,000/ mm³ in the absence of transfusion support (platelet transfusion within 7 days prior to screening) c. Hemoglobin < 8 g/dL (< 4.9 mmol/L) (it is not permissible to transfuse a subject to reach this level) d. Serum Creatinine Clearance (CrCl) < 45 mL/min e. Corrected serum calcium > 13.5 mg/dL (> 3.4 mmol/L) f. Serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2.5 × upper limit of normal (ULN) g. Serum total bilirubin > 1.5 × ULN or > 3.0 mg/dL for subjects with documented Gilbert's syndrome h. International ratio (INR) or partial thromboplastin time (PTT) > 1.5 × ULN, or history of Grade 2 hemorrhage within 30 days, or subject requires ongoing treatment with chronic, therapeutic dosing of anticoagulants (eg, warfarin, low molecular weight heparin, Factor Xa inhibitors). Echocardiogram (ECHO) or multi-gated acquisition (MUGA) with left ventricular ejection fraction < 45%. For Cohort 1b, previous treatment with any GPRC5D-targeted therapy or T-cell engagers. For Cohort 1b, known allergies, hypersensitivity, or intolerance to talquetamab or its excipients (please refer to TALVEYTM Product Information). Inadequate pulmonary function defined as oxygen saturation (SaO₂) < 92 % on room air. Ongoing treatment with chronic immunosuppressants (eg, cyclosporine or systemic steroids at any dose). Intermittent topical, inhaled or intranasal corticosteroids are allowed. Previous history of an allogeneic hematopoietic stem cell transplantation or treatment with any gene therapy-based therapeutic for cancer or investigational cellular therapy for cancer or BCMA targeted therapy. Subject has received ASCT within 12 weeks prior to leukapheresis. Subject has history of primary immunodeficiency. Subject is positive for human immunodeficiency virus (HIV-1), chronic or active hepatitis B or active hepatitis A or C. Subject has uncontrolled systemic fungal, bacterial, viral or other infection (including tuberculosis) despite appropriate antibiotics or other treatment.

Calendario

(Última actualización: 12/05/2026)

Autorización 19/10/2018	Inicio de Ensayo 04/01/2019	Inclusión Primer Paciente 21/01/2019	Interrumpido No aportado	Reiniciado No aportado
--	--	---	---	---

Fin de reclutamiento 29/07/2020	Fin prematuro (España) No aportado	Fin prematuro (Global) No aportado	Fin del ensayo en España 20/10/2025	Fin del ensayo global 15/01/2026
--	---	---	--	---

Promotor

Celgene Corp. United States

Route 206 And Province Line Road

Contact Person

GSM-CT

003223527611

mg-gsm-ct@bms.com

Monetary support: N/A

Tipo de promotor: Comercial

Ceim

CEIm de la Comunidad Foral de Navarra

C/ Irunlarrea, 3 31008 Pamplona

ceic@cfnavarra.es

Centros

Cerrado (10/04/2026)	CLINICA UNIVERSIDAD DE NAVARRA Pamplona/Iruña NAVARRA Servicio de Hematología y Hemoterapia
	COMPLEJO ASISTENCIAL UNIVERSITARIO DE SALAMANCA Salamanca SALAMANCA Departamento de Hematología

Medicamentos

idecabtagene vicleucel CELL SUSPENSION FOR INJECTION INTRAVENOUS
—
Principios Activos: N/A
Huérfano Experimental

Sin resultados

A study to assess the efficacy and safety of bb2121 in people who have Myeloma that is not responsive after treatment or who had Myeloma which has returned after a period of treatment

State	Type of participants	Age Ranges
Finished CT	Not provided	Older than 64 , Adults (18-64 years)
Gender	Phases	Expected Participants
Both	Phase II	228
Results	Low level of intervention	Rare disease
No results	No	Yes
Geographic coverage	Areas of the study	Advanced therapy
Undetermined	treatment, safety, effectiveness, pharmacokinetics, pharmacodynamics, pharmacogenomics	Gene therapy

Information

Identifier

2023-505183-10-00 (CTIS)

Protocol Code

bb2121-MM-002

Transitioned 2018-000264-28

Therapeutic area

Diseases [C] - Cancer [C04]

Investigated Disease

Relapsed and refractory multiple myeloma (RRMM), multiple myeloma (MM) with progression within 18 months of initial treatment/ or newly diagnosed multiple myeloma (NDMM) with suboptimal response post autologous stem cell transplant (ASCT) (Cohort 3 only)

Scientific Title

A PHASE 2, MULTI-COHORT, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BB2121 IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA AND IN SUBJECTS WITH CLINICAL HIGH-RISK MULTIPLE MYELOMA

Rationale

Not provided

Main Objective

The primary objective of the study is to evaluate the efficacy of bb2121, of bb2121 in combination with lenalidomide maintenance, and of bb2121 with talquetamab as bridging therapy

Primary Endpoints

Overall response rate (ORR) (Cohort 1)

Complete response (CR) rate Cohort 1b, Cohort 2a, Cohort 2b, Cohort 2c, and Cohort 3

Temporary moments of secondary assessment

Not provided

Secondary Objective

Evaluate additional efficacy parameters of bb2121

Characterize the expansion and persistence of chimeric antigen receptor (CAR) + T cells, in the peripheral blood (cellular kinetics-pharmacokinetics [PK])

Evaluate the development of an anti-CAR antibody response

Evaluate changes in health-related quality of life (HRQoL)

Cohort 3 only: Evaluate additional efficacy parameters of bb2121 in combination with lenalidomide maintenance

Cohort 3 only: Evaluate feasibility of initiating lenalidomide maintenance therapy post-bb2121 infusion

Secondary Endpoints

Complete response (CR) rate (Cohort 1)

Overall response rate (ORR) Cohort 1b, 2a, b, and Cohort 3

Very good partial response (VGPR) rate (Cohort 2c)

Time to response (TTR)

Duration of response (DoR)

Progression-free survival (PFS)

Time to progression (TTP)
 Overall survival (OS)
 Pharmacokinetics
 Immunogenicity
 Health-related Quality of Life (HRQoL)
 Feasibility of lenalidomide maintenance therapy post-bb2121 infusion (Cohort 3)

Temporary moments of secondary assessment

Not provided

Inclusion criteria

Subject is 18 years of age at the time of signing the informed consent form (ICF) Male subjects must: Practice true abstinence or agree to use a condom during sexual contact with a pregnant female or a FCBP, even if he has undergone a successful vasectomy from screening until at least 1 year following LD chemotherapy Refrain from tissue donation including sperm or any other tissue/blood/organ donations from screening until at least 1 year following LD chemotherapy. Cohorts 1 and 2 only, subject has measurable disease, defined as: M-protein (serum protein electrophoresis [sPEP] or urine protein electrophoresis [uPEP]): sPEP 0.5 g/dL or uPEP 200 mg/24 hours and/or Light chain MM without measurable disease in the serum or urine: Serum immunoglobulin free light chain 10 mg/dL and abnormal serum immunoglobulin kappa lambda free light chain ratio Subjects with one of the following cohort specific requirements: Cohort 1 RRMM subjects with 3 prior anti-myeloma treatment regimens: Subject must have received at least 3 prior anti-myeloma treatment regimens. Note: induction with or without hematopoietic stem cell transplant and with or without maintenance therapy is considered a single regimen Subject must have undergone at least 2 consecutive cycles of treatment for each regimen, unless PD was the best response to the regimen Subject must have received prior treatment with a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 antibody Subject has evidence of PD on or within 60 days of the most recent prior treatment regimen Subject achieved a response (minimal response [MR] or better) to at least 1 prior treatment regimen Cohort 2 subjects with 1 prior anti-myeloma treatment regimen: Subject must have received only 1 prior anti-myeloma treatment regimen. Note: induction with or without hematopoietic stem cell transplant and with or without maintenance therapy is considered a single regimen Subject must have the following HR factors: Early relapse defined as: Cohort 2a: PD < 18 months since date of start of initial therapy. Initial therapy must contain induction, ASCT (single or tandem) and lenalidomide containing maintenance Cohort 2b: PD < 18 months since date of start of initial therapy which must contain at minimum, a proteasome inhibitor, an immunomodulatory agent and dexamethasone Cohort 2c: Subject must have received minimum 3 cycles of induction therapy which must contain at minimum, a proteasome inhibitor, an immunomodulatory agent and dexamethasone. Subjects must have had ASCT (single or tandem) AND < VGPR (excluding PD) at first assessment between 70 to 110 days after last ASCT, with initial therapy without consolidation and maintenance Subject must have Eastern Cooperative Oncology Group (ECOG) performance status 1 Subject must have recovery to Grade 1 or baseline of any nonhematologic toxicities due to prior treatments, excluding alopecia and Grade 2 neuropathy Subject must have adequate vascular access for leukapheresis Subject must understand and voluntarily sign an ICF prior to any study-related assessments/procedures being conducted Subject is willing and able to adhere to the study visit schedule and other protocol requirements as well as agrees to continued follow up for up to 15 years as mandated by the regulatory guidelines for gene therapy trials Female subjects of childbearing potential (FCBP3) must: Have a negative pregnancy test(s) as verified by the Investigator, prior to the first dose of study treatment. This applies even if the subject practices true abstinence from heterosexual contact: -All subjects who receive LD chemotherapy/bb2121: Have negative pregnancy tests as verified by the Investigator, prior to LD chemotherapy. Either commit to true abstinence from heterosexual contact or agree to use, and be able to comply with highly effective measures of contraception without interruption, from screening through at least 1 year following LD chemotherapy. Contraception for FCBP must include highly effective methods of contraception from screening until -All subjects receiving LD chemotherapy/bb2121: until at least 1 year following LD chemotherapy. Agree to abstain from breastfeeding during study participation for at least 1 year following LD

chemotherapy. Refrain from tissue donation including egg cell donation or any other tissue/blood/organ donations until at least 1 year following LD chemotherapy.

Exclusion criteria

Subject used any investigational agents within 14 days prior to leukapheresis. Subject with prior history of malignancies, other than MM, unless the subject has been free of the disease for 5 years with the exception of the following noninvasive malignancies: a. Basal cell carcinoma of the skin b. Squamous cell carcinoma of the skin c. Carcinoma in situ of the cervix d. Carcinoma in situ of the breast e. Incidental histologic finding of prostate cancer (T1a or T1b using the TNM [tumor, nodes, metastasis] clinical staging system) or prostate cancer that is curative. Subject is a female who is pregnant, nursing, or breastfeeding, or who intends to become pregnant during participation in the study. Subject received any of the following within the last 14 days prior to leukapheresis: a. Plasmapheresis b. Major surgery (as defined by the investigator) c. Radiation therapy other than local therapy for myeloma associated bone lesions d. Use of any systemic anti-myeloma drug therapy. Subject with known hypersensitivity to any component of bb2121 product, cyclophosphamide, fludarabine, and/or tocilizumab. Subject has any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study. Subject has any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study. This includes systemic fungal, bacterial, viral, or other infection that is uncontrolled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antimicrobial treatment) or requiring IV antimicrobials for management. Subject has any condition that confounds the ability to interpret data from the study. Subject with known central nervous system (CNS) involvement with myeloma. Subject has clinical evidence of pulmonary leukostasis and disseminated intravascular coagulation. History or presence of clinically relevant CNS pathology such as epilepsy, seizure, paresis, aphasia, stroke, subarachnoid hemorrhage or other CNS bleed, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, or psychosis. Subject with a history of Class III or IV congestive heart failure (CHF) or severe nonischemic cardiomyopathy, unstable or poorly controlled angina, myocardial infarction, or ventricular arrhythmia within the previous 6 months prior to starting study treatment. Subject with active or history of plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes), or clinically significant amyloidosis. Subject has nonsecretory MM. Subject has any of the following laboratory abnormalities: a. Absolute neutrophil count (ANC) < 1,000/L b. Platelet count < 50,000/ mm³ in the absence of transfusion support (platelet transfusion within 7 days prior to screening) c. Hemoglobin < 8 g/dL (< 4.9 mmol/L) (it is not permissible to transfuse a subject to reach this level) d. Serum Creatinine Clearance (CrCl) < 45 mL/min e. Corrected serum calcium > 13.5 mg/dL (> 3.4 mmol/L) f. Serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2.5 × upper limit of normal (ULN) g. Serum total bilirubin > 1.5 × ULN or > 3.0 mg/dL for subjects with documented Gilbert's syndrome h. International ratio (INR) or partial thromboplastin time (PTT) > 1.5 × ULN, or history of Grade 2 hemorrhage within 30 days, or subject requires ongoing treatment with chronic, therapeutic dosing of anticoagulants (eg, warfarin, low molecular weight heparin, Factor Xa inhibitors). Echocardiogram (ECHO) or multi-gated acquisition (MUGA) with left ventricular ejection fraction < 45%. For Cohort 1b, previous treatment with any GPRC5D-targeted therapy or T-cell engagers. For Cohort 1b, known allergies, hypersensitivity, or intolerance to talquetamab or its excipients (please refer to TALVEY™ Product Information). Inadequate pulmonary function defined as oxygen saturation (SaO₂) < 92 % on room air. Ongoing treatment with chronic immunosuppressants (eg, cyclosporine or systemic steroids at any dose). Intermittent topical, inhaled or intranasal corticosteroids are allowed. Previous history of an allogeneic hematopoietic stem cell transplantation or treatment with any gene therapy-based therapeutic for cancer or investigational cellular therapy for cancer or BCMA targeted therapy. Subject has received ASCT within 12 weeks prior to leukapheresis. Subject has history of primary immunodeficiency. Subject is positive for human immunodeficiency virus (HIV-1), chronic or active hepatitis B or active hepatitis A or C. Subject has uncontrolled systemic fungal, bacterial, viral or other infection (including tuberculosis) despite appropriate antibiotics or other treatment.

Calendar

(Last Update: 12/05/2026)

Authorization 19/10/2018	Start of Trial 04/01/2019	First patient inclusion 21/01/2019	Halted Not aported	Restarted Not aported
End of recruitment 29/07/2020	Premature end (Spain) Not aported	Premature End (Global) Not aported	Trial end (Spain) 20/10/2025	Trial end (Global) 15/01/2026

Sponsor

Celgene Corp. United States

Route 206 And Province Line Road

Contact Person

GSM-CT

003223527611

mg-gsm-ct@bms.com

Monetary support: N/A

Sponsor type: Commercial

Ceim

CEIm de la Comunidad Foral de Navarra

C/ Irunlarrea, 3 31008 Pamplona

ceic@cfnavarra.es

Sites

Closed (10/04/2026)	CLINICA UNIVERSIDAD DE NAVARRA	COMPLEJO ASISTENCIAL UNIVERSITARIO DE SALAMANCA
	Pamplona/Iruña	Salamanca
	NAVARRA	SALAMANCA
	Servicio de Hematología y Hemoterapia	Departamento de Hematología

Medication

idecabtagene vicleucel
CELL SUSPENSION FOR INJECTION
INTRAVENOUS
-
Active Principles: N/A
Orphan
Experimental

No results